UroGen Pharma Highlights JELMYTO's Long-Term Efficacy at SUO Annual Meeting

UroGen Pharma Showcases Promising Long-Term Results for JELMYTO at SUO Annual Meeting

UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative treatments for urothelial and specialty cancers, presents compelling data on its FDA-approved product JELMYTO (mitomycin) during the Society for Urologic Oncology (SUO) annual meeting in Dallas, Texas. This long-term follow-up study, part of the OLYMPUS trial, evaluates the effectiveness of JELMYTO in treating low-grade upper tract urothelial cancer (LG-UTUC). Results reveal that out of 71 patients treated with JELMYTO, 41 achieved a complete response, demonstrating a median duration of response of 47.8 months, with a median follow-up of 28.1 months. These findings suggest that JELMYTO may provide robust long-term control of LG-UTUC, addressing a significant need for chronic management of this cancer type.

Dr. Brian Hu, a key researcher involved in the study, emphasizes the potential of JELMYTO to offer long-lasting recurrence-free intervals. This aspect is crucial as patients with LG-UTUC often face the challenge of tumor recurrence and the subsequent need for more invasive treatment options. UroGen's Chief Medical Officer, Dr. Mark Schoenberg, underscores that the management of relapse and preservation of kidney function are vital objectives in treating LG-UTUC. The compelling evidence from the long-term study supports JELMYTO’s role in enhancing patient quality of life by providing an effective and less invasive alternative to traditional therapies.

Despite the positive outcomes, the study acknowledges limitations due to its post-hoc nature and potential selection bias from the cohort of 20 patients involved in the long-term follow-up. UroGen remains committed to addressing these challenges through further research. JELMYTO utilizes a unique mitomycin-containing reverse thermal gel that can be administered via ureteral catheter or nephrostomy tube, transitioning from a viscous liquid to a semi-solid gel at body temperature. This innovative delivery system allows for prolonged chemoablative therapy in the upper urinary tract, potentially extending the therapeutic impact of the drug.

In addition to its focus on JELMYTO, UroGen continues to bolster its workforce, recently granting inducement restricted stock units (RSUs) to 35 new employees. These RSUs, part of UroGen's ongoing commercialization efforts, will vest over three years and reflect the company's commitment to enhancing its product offerings and pipeline development. UroGen is known for its proprietary RTGel® technology, which enhances drug delivery and efficacy, further positioning the company as a leader in non-surgical solutions for low-grade non-muscle invasive bladder cancer. For more information, UroGen encourages interested parties to visit their website or follow them on social media.